American Well Corporation (NYSE:AMWL) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET
Company Participants
Sue Dooley - Head of IR
Ido Schoenberg - Chairman & Co-CEO
Bob Shepardson - CFO
Conference Call Participants
Charles Rhyee - Cowen
Craig Hettenbach - Morgan Stanley
Stan Berenshteyn - Wells Fargo securities
David Larse - BTIG
Jessica Tassan - Piper Sandler
Cindy Motz - Goldman Sachs
Allen Lutz - Bank of America Merrill Lynch
Operator
Good afternoon. My name is Mellissa, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amwell Q3 2022 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.
I would now like to hand the call over to Sue Dooley, Head of Investor Relations of Amwell. You may begin.
Sue Dooley
Hello, everyone. Welcome to Amwell's conference call to discuss our third fiscal quarter of 2022. This is Sue Dooley of Amwell Investor Relations. Joining me today are Amwell's Chairman and CEO, Dr. Ito Schoenberg; and Bob Shepherdson, our CFO. Earlier today, we distributed a press release detailing our announcement. The release is posted on our website at investors.amwell.com and is also available from normal new sources. This conference call is being webcast live on the Investor Relations page of our website, where a replay will be archived.
Before we begin our prepared remarks, I'd like to take this opportunity to remind you that during the course of this call, we will make forward-looking statements regarding projected operating results and anticipated market opportunities. This forward-looking information is subject to the risks and uncertainties described in our filings with the SEC, and actual results or events may differ materially. Except as required by law, we undertake no obligation to update or revise these forward-looking statements.
On this call, we'll refer to both GAAP and non-GAAP financial measures. A reconciliation of GAAP to non-GAAP financial measures is provided in our posted earnings release.
With that, I'd like to turn the call over to Ido.
Ido Schoenberg
Thank you, Sue. Q3 was another important quarter for our company. We continue to execute well, through our time of transition. The market is responding well to converge, a platform that is designed to enable and empower the innovative healthcare organizations who are leading the way to a hybrid care future. I'll start by reviewing some highlights of the quarter. Then I'll take a moment to discuss the market for our solution. Bob will then review some key metrics, our financial results and our 2022 guidance. After that, we'll open the discussion with your questions.